Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioteBTMD +2.27%70 EV-to-EBIT is 5.34 as of Aug. 03, 2026, which is 7% below its 10-year median of 5.72. GuruFocus rates BTMD with a GF Score™ of 70/100 and a GF Value™ of $3.07 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 471 Healthcare Providers & Services companies, Biote ranks better than 89.38% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biote's Enterprise Value is $178.9 Mil.
Biote's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $33.5 Mil. Therefore, Biote's EV-to-EBIT for today is 5.34.
The historical rank and industry rank for Biote's EV-to-EBIT or its related term are showing as below:
BTMD'
s EV-to-EBIT Range Over the Past 10 Years
Min: -12.25 Med: 5.72 Max: 40.73
Current: 5.34
During the past 7 years, the highest EV-to-EBIT of Biote was 40.73. The lowest was -12.25. And the median was 5.72.
BTMD's EV-to-EBIT is ranked better than 89.38% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs BTMD: 5.34
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Biote's Enterprise Value for the quarter that ended in Mar. 2026 was $151.7 Mil.
Biote's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote EV-to-EBIT Related Terms
Biote EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Biote's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Biote's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Biote's EV-to-EBIT falls into.
Biote's current Enterprise Value is $178.9 Mil.
Biote's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote (BTMD) has a EV-to-EBIT of 5.34 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biote and its competitors. This is near median its historical median of 5.72. According to the industry distribution chart, Biote ranks #50 out of 471 companies in the Healthcare Providers & Services industry, placing it in the top 10.6%.
Is Biote's EV-to-EBIT too high?
Biote's current EV-to-EBIT of 5.34 is near median its 10-year median of 5.72. The Healthcare Providers & Services industry median EV-to-EBIT is 15.84. Biote's value of 5.34 is 66.3% below this industry median. Based on the distribution chart, Biote ranks #50 out of 471 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Biote has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's EV-to-EBIT compare to DCGO and PARK?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #50 out of 471 companies for EV-to-EBIT. This places Biote in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.84. Biote's value of 5.34 is 66.3% below this benchmark. While the company's 10-year median is 5.72 vs. the industry median of 15.84, Biote has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biote's current EV-to-EBIT of 5.34 is 66.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biote and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current EV-to-EBIT is 5.34, which is near median its own 10-year median of 5.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $2.23 — trading 27.4% below its estimated fair value. The current EV-to-EBIT is 5.34, which is near median its 10-year median of 5.72 and 66.3% below the Healthcare Providers & Services industry median of 15.84. Biote's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Biote (BTMD), the current EV-to-EBIT is 5.34 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biote (BTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Biote stock appears to be undervalued.
The current stock price of $2.23 is trading 27.4% below its estimated GF Value™ of $3.07.
GuruFocus considers Biote to be Modestly Undervalued.
Key valuation signals for BTMD:
EV-to-EBIT: 5.34 (near median its 10-year median of 5.72)
GF Value™: $3.07 vs. price of $2.23 (27.4% below fair value)
Industry Position: 66.3% below the Healthcare Providers & Services median (#50 of 471)
No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
70GF Score
Get the complete analysis for BTMD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMD has been successfully added to your 
